$Phathom Pharmaceuticals (PHAT.US)$ 在今天发布的一份报告中，尼德姆维持了对Phathom Pharmicals（—）的买入评级，目标股价为26.00美元。
约瑟夫·斯金格之所以给出买入评级，是因为围绕Phathom Pharmicals最近发展的多种因素。斯金格的乐观情绪源于Voquezna批准用于非侵蚀性胃食管反流病（NERD），该市场比该药物先前的适应症要大得多。此次标签扩张预计将有...

$Soligenix (SNGX.US)$ shares skyrocketed more than 400% in recent Tuesday trading after the company reported positive results of a study evaluating extended HyBryte treatment in patients with early-stage cutaneous T-cell lymphoma.
The company said six patients were enrolled in the Phase 3 FLASH study and treated with HyBryte over a period of up to 44 weeks, and they responded positively to the therapy with 75% achieving "treatment success."

$Anew Medical (WENA.US)$
ANEW Medical宣布其Klotho基因序列和基因传递系统用于治疗认知减退、记忆丧失、痴呆和其他神经退行性疾病的专利已在欧洲获得批准并颁发了一项名为 EP3377091B1 的专利，此后，该公司股价走高